Combined FDG and NaF PET/CT study in patients (pts) with metastatic genitourinary tumors (mGU) treated with cabozantinib + nivolumab +/- ipilimumab (CaboNivo+/-Ipi).

Jeffrey Lin,Amir Mortazavi,Mark N. Stein,Sumanta K. Pal,Nicole N. Davarpanah,Rosa Nadal,Deneise C Francis,Marilise Anne Berniger,Paul Monk,Jeffrey S. Kempf,Murray Becker,Levi Sokol,Yolanda McKinney,Michael V. Knopp,Chadwick Wright,Alex Jung,Peter L. Choyke,Esther Mena,Liza Lindenberg,Andrea B. Apolo

Combined FDG and NaF PET/CT study in patients (pts) with metastatic genitourinary tumors (mGU) treated with cabozantinib + nivolumab +/- ipilimumab (CaboNivo+/-Ipi).

2017

e16017Background: The primary objective of the study is to assess the feasibility of obtaining combined FDG and NaF PET/CT in detecting soft-tissue and bone metastatic disease in mGU pts treated wi...

Keywords:

Ipilimumab
Nivolumab
Genitourinary system
Cancer research
Pathology
PET-CT
Medicine
Cabozantinib
in patient
Radiology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations